39,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
20 °P sammeln
  • Broschiertes Buch

The management of differentiated thyroid cancers is a hotly debated topic, especially when it comes to defining the best treatment modalities using radioactive iodine as a complement to surgery. Papillary thyroid micro-carcinomas (PCM) with lymph node extension are no exception to this rule. While there is a consensus for low-risk PCMs, therapeutic attitudes diverge as to complementary iratherapy for intermediate- to high-risk PCMs.We conducted a study to evaluate the post-surgical complementary iratherapy protocol proposed for patients followed for PCM with lymph node extension in the Nuclear…mehr

Produktbeschreibung
The management of differentiated thyroid cancers is a hotly debated topic, especially when it comes to defining the best treatment modalities using radioactive iodine as a complement to surgery. Papillary thyroid micro-carcinomas (PCM) with lymph node extension are no exception to this rule. While there is a consensus for low-risk PCMs, therapeutic attitudes diverge as to complementary iratherapy for intermediate- to high-risk PCMs.We conducted a study to evaluate the post-surgical complementary iratherapy protocol proposed for patients followed for PCM with lymph node extension in the Nuclear Medicine Department of the Salah Azaiez Institute. These patients underwent either high-dose or low-dose complementary iratherapy, with a 6-month post-cure and long-term evaluation. We concluded that the efficacy of low-dose treatment was non-inferior to that of high-dose treatment for patients followed for PCM with lymph node extension.
Autorenporträt
Dr IMENE YEDDES, Doctor of Medicine since 2009 and Associate Professor of Biophysics and Nuclear Medicine since 2016, working at the Salah AZAIEZ Institute, TUNISIA's cancer center, and lecturer at the Tunis Faculty of Medicine.